Effect of inhibition of the Ubiquitin-Proteasome System and Hsp90 on growth and survival of Rhabdomyosarcoma cells in vitro

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Peron, Marica ^a   Bonvini, Paolo ^a,b   Rosolen, Angelo ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b Fondazione Citta della Speranza   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ALVESPIMYCIN; BORTEZOMIB; CELL PROTEIN; CHLOROQUINE; FLUORESCEIN ISOTHIOCYANATE; HEAT SHOCK PROTEIN 90; LIPOCORTIN 5; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROPIDIUM IODIDE; PROTEASOME; PROTEIN LC3 I; RAPAMYCIN; UBIQUITIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CELL VACUOLE; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; PROTEIN CLEAVAGE; RHABDOMYOSARCOMA; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOPHAGY; BENZOQUINONES; BORONIC ACIDS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; RHABDOMYOSARCOMA; UBIQUITIN;

EID: 84861981005     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-233     Document Type: Article

References (60)

1. Wachtel M, Runge T, Leuschner I, Stegmaier S, Koscielniak E, Treuner J, Odermatt B, Behnke S, Niggli FK, Schafer BW. Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry. J Clin Oncol 2006, 24(5):816-822. 10.1200/JCO.2005.03.4934, 16391296.
2. Merlino G, Helman LJ. Rhabdomyosarcoma-working out the pathways. Oncogene 1999, 18(38):5340-5348. 10.1038/sj.onc.1203038, 10498887.
3. Harms D. Alveolar rhabdomyosarcoma: a prognostically unfavorable rhabdomyosarcoma type and its necessary distinction from embryonal rhabdomyosarcoma. Curr Top Pathol 1995, 89:273-296. 10.1007/978-3-642-77289-4_14, 7882714.
4. Newton WA, Soule EH, Hamoudi AB, Reiman HM, Shimada H, Beltangady M, Maurer H. Histopathology of childhood sarcomas, Intergroup Rhabdomyosarcoma Studies I and II: clinicopathologic correlation. J Clin Oncol 1988, 6(1):67-75.
5. Davis RJ, D'Cruz CM, Lovell MA, Biegel JA, Barr FG. Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. Cancer Res 1994, 54(11):2869-2872.
6. Bennicelli JL, Edwards RH, Barr FG. Mechanism for transcriptional gain of function resulting from chromosomal translocation in alveolar rhabdomyosarcoma. Proc Natl Acad Sci U S A 1996, 93(11):5455-5459. 10.1073/pnas.93.11.5455, 39267, 8643596.
7. Bersani F, Taulli R, Accornero P, Morotti A, Miretti S, Crepaldi T, Ponzetto C. Bortezomib-mediated proteasome inhibition as a potential strategy for the treatment of rhabdomyosarcoma. Eur J Cancer 2008, 44(6):876-884. 10.1016/j.ejca.2008.02.022, 18342500.
8. Lesko E, Gozdzik J, Kijowski J, Jenner B, Wiecha O, Majka M. HSP90 antagonist, geldanamycin, inhibits proliferation, induces apoptosis and blocks migration of rhabdomyosarcoma cells in vitro and seeding into bone marrow in vivo. Anticancer Drugs 2007, 18(10):1173-1181. 10.1097/CAD.0b013e3282ef532d, 17893518.
9. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004, 4(5):349-360. 10.1038/nrc1361, 15122206.
10. Milano A, Iaffaioli RV, Caponigro F. The proteasome: a worthwhile target for the treatment of solid tumours?. Eur J Cancer 2007, 43(7):1125-1133. 10.1016/j.ejca.2007.01.038, 17379504.
11. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001, 61(7):3071-3076.
12. Smith V, Sausville EA, Camalier RF, Fiebig HH, Burger AM. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models. Cancer Chemother Pharmacol 2005, 56(2):126-137. 10.1007/s00280-004-0947-2, 15841378.
13. Neerken S, Ma YZ, Aschenbrucker J, Schmidt KA, Nowak FR, Permentier HP, Aartsma TJ, Gillbro T, Amesz J. Kinetics of absorbance and anisotropy upon excited state relaxation in the reaction center core complex of a green sulfur bacterium. Photosynth Res 2000, 65(3):261-268. 10.1023/A:1010647205220, 16228492.
14. Ochel HJ, Eichhorn K, Gademann G. Geldanamycin: the prototype of a class of antitumor drugs targeting the heat shock protein 90 family of molecular chaperones. Cell Stress Chaperones 2001, 6(2):105-112. 10.1379/1466-1268(2001)006<0105:GTPOAC>2.0.CO;2, 434387, 11599571.
15. Kim S, Kang J, Hu W, Evers BM, Chung DH. Geldanamycin decreases Raf-1 and Akt levels and induces apoptosis in neuroblastomas. Int J Cancer 2003, 103(3):352-359. 10.1002/ijc.10820, 12471618.
16. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005, 5(10):761-772. 10.1038/nrc1716, 16175177.
17. Mimnaugh EG, Xu W, Vos M, Yuan X, Isaacs JS, Bisht KS, Gius D, Neckers L. Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity. Mol Cancer Ther 2004, 3(5):551-566.
18. Pandey UB, Nie Z, Batlevi Y, McCray BA, Ritson GP, Nedelsky NB, Schwartz SL, DiProspero NA, Knight MA, Schuldiner O. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature 2007, 447(7146):859-863.
19. Palacios C, Martin-Perez R, Lopez-Perez AI, Pandiella A, Lopez-Rivas A. Autophagy inhibition sensitizes multiple myeloma cells to17-dimethylaminoethylamino-17-demethoxygeldanamycin-induced apoptosis. Leuk Res 34(11):1533-1538.
20. Finn PF, Mesires NT, Vine M, Dice JF. Effects of small molecules on chaperone-mediated autophagy. Autophagy 2005, 1(3):141-145. 10.4161/auto.1.3.2000, 16874031.
21. Kaushik S, Massey AC, Mizushima N, Cuervo AM. Constitutive activation of chaperone-mediated autophagy in cells with impaired macroautophagy. Mol Biol Cell 2008, 19(5):2179-2192. 10.1091/mbc.E07-11-1155, 2366850, 18337468.
22. Massey AC, Kaushik S, Sovak G, Kiffin R, Cuervo AM. Consequences of the selective blockage of chaperone-mediated autophagy. Proc Natl Acad Sci U S A 2006, 103(15):5805-5810. 10.1073/pnas.0507436103, 1458654, 16585521.
23. Li W, Yang Q, Mao Z. Chaperone-mediated autophagy: machinery, regulation and biological consequences. Cell Mol Life Sci 2011, 68(5):749-763. 10.1007/s00018-010-0565-6, 20976518.
24. Nikaido T, Takada T, Kitasako Y, Ogata M, Shimada Y, Yoshikawa T, Nakajima M, Otsuki M, Tagami J, Burrow MF. Retrospective study of five-year clinical performance of direct composite restorations using a self-etching primer adhesive system. Dent Mater J 2006, 25(3):611-615. 10.4012/dmj.25.611, 17076335.
25. Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, Kominami E, Ohsumi Y, Yoshimori T. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 2000, 19(21):5720-5728. 10.1093/emboj/19.21.5720, 305793, 11060023.
26. Klionsky DJ, Abeliovich H, Agostinis P, Agrawal DK, Aliev G, Askew DS, Baba M, Baehrecke EH, Bahr BA, Ballabio A. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 2008, 4(2):151-175. 2654259, 18188003.
27. Martin DE, Hall MN. The expanding TOR signaling network. Curr Opin Cell Biol 2005, 17(2):158-166. 10.1016/j.ceb.2005.02.008, 15780592.
28. Qiao L, Zhang J. Inhibition of lysosomal functions reduces proteasomal activity. Neurosci Lett 2009, 456(1):15-19. 10.1016/j.neulet.2009.03.085, 19429125.
29. Pan T, Kondo S, Zhu W, Xie W, Jankovic J, Le W. Neuroprotection of rapamycin in lactacystin-induced neurodegeneration via autophagy enhancement. Neurobiol Dis 2008, 32(1):16-25. 10.1016/j.nbd.2008.06.003, 18640276.
30. Du Y, Yang D, Li L, Luo G, Li T, Fan X, Wang Q, Zhang X, Wang Y, Le W. An insight into the mechanistic role of p53-mediated autophagy induction in response to proteasomal inhibition-induced neurotoxicity. Autophagy 2009, 5(5):663-675. 10.4161/auto.5.5.8377, 19337030.
31. Cullinan SB, Whitesell L. Heat shock protein 90: a unique chemotherapeutic target. Semin Oncol 2006, 33(4):457-465. 10.1053/j.seminoncol.2006.04.001, 16890800.
32. Montagut C, Rovira A, Albanell J. The proteasome: a novel target for anticancer therapy. Clin Transl Oncol 2006, 8(5):313-317. 10.1007/s12094-006-0176-8, 16760005.
33. Lauricella M, D'Anneo A, Giuliano M, Calvaruso G, Emanuele S, Vento R, Tesoriere G. Induction of apoptosis in human osteosarcoma Saos-2 cells by the proteasome inhibitor MG132 and the protective effect of pRb. Cell Death Differ 2003, 10(8):930-932. 10.1038/sj.cdd.4401251, 12868001.
34. Lu G, Punj V, Chaudhary PM. Proteasome inhibitor Bortezomib induces cell cycle arrest and apoptosis in cell lines derived from Ewing's sarcoma family of tumors and synergizes with TRAIL. Cancer Biol Ther 2008, 7(4):603-608. 10.4161/cbt.7.4.5564, 18223318.
35. Yan XB, Yang DS, Gao X, Feng J, Shi ZL, Ye Z. Caspase-8 dependent osteosarcoma cell apoptosis induced by proteasome inhibitor MG132. Cell Biol Int 2007, 31(10):1136-1143. 10.1016/j.cellbi.2007.03.037, 17493842.
36. Maki RG, Kraft AS, Scheu K, Yamada J, Wadler S, Antonescu CR, Wright JJ, Schwartz GK. A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas. Cancer 2005, 103(7):1431-1438. 10.1002/cncr.20968, 15739208.
37. Gerecitano J, Portlock C, Hamlin P, Moskowitz CH, Noy A, Straus D, Schulman P, Dumitrescu O, Sarasohn D, Pappanicholaou J. Phase I trial of weekly and twiceweekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-hodgkin lymphoma. Clin Cancer Res 2011, 17(8):2493-2501. 10.1158/1078-0432.CCR-10-1498, 21346146.
38. Furman RR, Martin P, Ruan J, Cheung YK, Vose JM, LaCasce AS, Elstrom R, Coleman M, Leonard JP. Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma. Cancer 2010, 116(23):5432-5439. 10.1002/cncr.25509, 20665890.
39. Bagatell R, Beliakoff J, David CL, Marron MT, Whitesell L. Hsp90 inhibitors deplete key anti-apoptotic proteins in pediatric solid tumor cells and demonstrate synergistic anticancer activity with cisplatin. Int J Cancer 2005, 113(2):179-188. 10.1002/ijc.20611, 15455381.
40. Martins AS, Ordonez JL, Garcia-Sanchez A, Herrero D, Sevillano V, Osuna D, Mackintosh C, Caballero G, Otero AP, Poremba C. A pivotal role for heat shock protein 90 in Ewing sarcoma resistance to anti-insulin-like growth factor 1 receptor treatment: in vitro and in vivo study. Cancer Res 2008, 68(15):6260-6270. 10.1158/0008-5472.CAN-07-3074, 18676850.
41. Richardson PG, Mitsiades CS, Laubach JP, Lonial S, Chanan-Khan AA, Anderson KC. Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers. Br J Haematol 2011, 152(4):367-379. 10.1111/j.1365-2141.2010.08360.x, 21219297.
42. Duus J, Bahar HI, Venkataraman G, Ozpuyan F, Izban KF, Al-Masri H, Maududi T, Toor A, Alkan S. Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma. Leuk Lymphoma 2006, 47(7):1369-1378. 10.1080/10428190500472123, 16923571.
43. Roue G, Perez-Galan P, Mozos A, Lopez-Guerra M, Xargay-Torrent S, Rosich L, Saborit-Villarroya I, Normant E, Campo E, Colomer D. The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78. Blood 2011, 117(4):1270-1279. 10.1182/blood-2010-04-278853, 21106982.
44. Sydor JR, Normant E, Pien CS, Porter JR, Ge J, Grenier L, Pak RH, Ali JA, Dembski MS, Hudak J. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI 504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci U S A 2006, 103(46):17408-17413. 10.1073/pnas.0608372103, 1635022, 17090671.
45. Smith MA, Morton CL, Phelps DA, Kolb EA, Lock R, Carol H, Reynolds CP, Maris JM, Keir ST, Wu J. Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program. Pediatr Blood Cancer 2008, 51(1):34-41. 10.1002/pbc.21508, 18260120.
46. Houghton PJ, Morton CL, Kolb EA, Lock R, Carol H, Reynolds CP, Keshelava N, Maris JM, Keir ST, Wu J. Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatr Blood Cancer 2008, 50(1):37-45. 10.1002/pbc.21214, 17420992.
47. Fratta P, Engel WK, McFerrin J, Davies KJ, Lin SW, Askanas V. Proteasome inhibition and aggresome formation in sporadic inclusion-body myositis and in amyloid-beta precursor protein-overexpressing cultured human muscle fibers. Am J Pathol 2005, 167(2):517-526. 10.1016/S0002-9440(10)62994-X, 1603556, 16049336.
48. Kirkin V, McEwan DG, Novak I, Dikic I. A role for ubiquitin in selective autophagy. Mol Cell 2009, 34(3):259-269. 10.1016/j.molcel.2009.04.026, 19450525.
49. Agarraberes FA, Dice JF. A molecular chaperone complex at the lysosomal membrane is required for protein translocation. J Cell Sci 2001, 114(Pt 13):2491-2499.
50. Salvador N, Aguado C, Horst M, Knecht E. Import of a cytosolic protein into lysosomes by chaperone-mediated autophagy depends on its folding state. J Biol Chem 2000, 275(35):27447-27456.
51. Majeski AE, Dice JF. Mechanisms of chaperone-mediated autophagy. Int J Biochem Cell Biol 2004, 36(12):2435-2444. 10.1016/j.biocel.2004.02.013, 15325583.
52. Bandyopadhyay U, Kaushik S, Varticovski L, Cuervo AM. The chaperone-mediated autophagy receptor organizes in dynamic protein complexes at the lysosomal membrane. Mol Cell Biol 2008, 28(18):5747-5763. 10.1128/MCB.02070-07, 2546938, 18644871.
53. Lamark T, Johansen T. Autophagy: links with the proteasome. Curr Opin Cell Biol 2010, 22(2):192-198. 10.1016/j.ceb.2009.11.002, 19962293.
54. Wu WK, Wu YC, Yu L, Li ZJ, Sung JJ, Cho CH. Induction of autophagy by proteasome inhibitor is associated with proliferative arrest in colon cancer cells. Biochem Biophys Res Commun 2008, 374(2):258-263. 10.1016/j.bbrc.2008.07.031, 18638451.
55. Ge PF, Zhang JZ, Wang XF, Meng FK, Li WC, Luan YX, Ling F, Luo YN. Inhibition of autophagy induced by proteasome inhibition increases cell death in human SHG-44 glioma cells. Acta Pharmacol Sin 2009, 30(7):1046-1052. 10.1038/aps.2009.71, 19575007.
56. Ding WX, Ni HM, Gao W, Chen X, Kang JH, Stolz DB, Liu J, Yin XM. Oncogenic transformation confers a selective susceptibility to the combined suppression of the proteasome and autophagy. Mol Cancer Ther 2009, 8(7):2036-2045. 10.1158/1535-7163.MCT-08-1169, 2711219, 19584239.
57. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008, 132(1):27-42. 10.1016/j.cell.2007.12.018, 2696814, 18191218.
58. Wei Y, Sinha S, Levine B. Dual role of JNK1-mediated phosphorylation of Bcl-2 in autophagy and apoptosis regulation. Autophagy 2008, 4(7):949-951. 2677707, 18769111.
59. Diaz-Troya S, Perez-Perez ME, Florencio FJ, Crespo JL. The role of TOR in autophagy regulation from yeast to plants and mammals. Autophagy 2008, 4(7):851-865.
60. Araki M, Motojima K. Hydrophobic statins induce autophagy in cultured human rhabdomyosarcoma cells. Biochem Biophys Res Commun 2008, 367(2):462-467. 10.1016/j.bbrc.2007.12.166, 18178158.